<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37896992</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Long COVID Prevalence and the Impact of the Third SARS-CoV-2 Vaccine Dose: A Cross-Sectional Analysis from the Third Follow-Up of the Borriana Cohort, Valencia, Spain (2020-2022).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1590</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines11101590</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In March 2020, a COVID-19 outbreak linked to mass gathering dinners at the Falles Festival in Borriana, Spain, resulted in an estimated attack rate of 42.6% among attendees.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In June 2022, we conducted a cross-sectional follow-up study of 473 adults aged 18 to 64 who attended the dinners at the Falles Festival in 2020, examining the cumulative experience after SARS-CoV-2 infection and vaccination responses. Data included demographic details, lifestyle habits, medical history, infection records, and vaccinations from a population-based vaccine registry. Blood samples were analyzed for SARS-CoV-2 antibodies and cellular immunity. We employed a doubly robust inverse-probability weighting analysis to estimate the booster vaccine dose's impact on long COVID prevalence and symptom count.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 28.1% of participants met the WHO criteria for long COVID, with older individuals showing higher rates. Long COVID diagnosis was less likely with factors including O blood group, higher occupational status, physical activity, three vaccine doses, strong SARS-CoV-2-S-reactive IFN&#x3b3;-producing-CD8+ response, and infection during the Omicron period. Increased age, high or low social activity, underlying health conditions, a severe initial COVID episode, and reinfection were associated with higher long COVID likelihood. A booster dose, compared to one or two doses, reduced long COVID risk by 74% (95% CI: 56% to 92%) and symptom count by 55% (95% CI: 32% to 79%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Long COVID was prevalent in a significant portion of those who contracted COVID-19, underscoring the need for sustained follow-up and therapeutic strategies. Vaccinations, notably the booster dose, had a substantial beneficial effect on long-term infection outcomes, affirming the vaccination's role in mitigating SARS-CoV-2 infection consequences.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dom&#xe8;nech-Montoliu</LastName><ForeName>Salvador</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Emergency Service, University Hospital de la Plana, 12540 Vila-real, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puig-Barber&#xe0;</LastName><ForeName>Joan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5783-0409</Identifier><AffiliationInfo><Affiliation>Vaccine Research Unit (AIV), Fundaci&#xf3;n para el Fomento de la Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de la Comunitat Valenciana (FISABIO), 46020 Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badenes-Marques</LastName><ForeName>Gema</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Emergency Service, University Hospital de la Plana, 12540 Vila-real, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil-Fortu&#xf1;o</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Microbiology Service, University Hospital de la Plana, 12540 Vila-real, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orrico-S&#xe1;nchez</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3780-3187</Identifier><AffiliationInfo><Affiliation>Vaccine Research Unit (AIV), Fundaci&#xf3;n para el Fomento de la Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de la Comunitat Valenciana (FISABIO), 46020 Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pac-Sa</LastName><ForeName>Mar&#xed;a Rosario</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Centro de Salud P&#xfa;blica de Castell&#xf3;n, 12003 Castell&#xf3; de la Plana, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perez-Olaso</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Microbiology Service, University Hospital de la Plana, 12540 Vila-real, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sala-Trull</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Emergency Service, University Hospital de la Plana, 12540 Vila-real, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Urbano</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9629-1601</Identifier><AffiliationInfo><Affiliation>Emergency Service, University Hospital de la Plana, 12540 Vila-real, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnedo-Pena</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1071-0984</Identifier><AffiliationInfo><Affiliation>Centro de Salud P&#xfa;blica de Castell&#xf3;n, 12003 Castell&#xf3; de la Plana, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Science, Universidad P&#xfa;blica de Navarra, 31006 Pamplona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NA</GrantID><Agency>Fundaci&#xf3;n para el Fomento de la Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de la Comunitat Valenciana</Agency><Country/></Grant><Grant><GrantID>NA</GrantID><Agency>Conseller&#xed;a de Sanitat Universal i Salut P&#xfa;blica</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2 vaccination</Keyword><Keyword MajorTopicYN="N">booster dose</Keyword><Keyword MajorTopicYN="N">cellular immunity</Keyword><Keyword MajorTopicYN="N">human</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">prevalence</Keyword><Keyword MajorTopicYN="N">risk factors</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>28</Day><Hour>11</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>28</Day><Hour>11</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>28</Day><Hour>1</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37896992</ArticleId><ArticleId IdType="pmc">PMC10611325</ArticleId><ArticleId IdType="doi">10.3390/vaccines11101590</ArticleId><ArticleId IdType="pii">vaccines11101590</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO . WHO Coronavirus (COVID-19) Dashboard. WHO; Geneva, Switzerland: 2023. Dashboard WHE.</Citation></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Wan E.Y. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi O.L., Hughes S.E., Turner G., Rivera S.C., McMullan C., Chandan J.S., TLC Study Group Symptoms, complications and management of long COVID: A review. J. R. Soc. Med. 2021;114:428&#x2013;442. doi: 10.1177/01410768211032850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/01410768211032850</ArticleId><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D., Sun A., Ssentongo A.E., Ba D.M., Parsons N., Poudel G.R., Chinchilli V.M. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. JAMA Netw. Open. 2021;4:e2128568. doi: 10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Haupert S.R., Zimmermann L., Shi X., Fritsche L.G., Mukherjee B. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or long COVID: A Meta-Analysis and Systematic Review. J. Infect. Dis. 2022;226:1593&#x2013;1607. doi: 10.1093/infdis/jiac136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Callard F., Perego E. How and why patients made Long Covid. Soc. Sci. Med. 2021;268:113426. doi: 10.1016/j.socscimed.2020.113426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2020.113426</ArticleId><ArticleId IdType="pmc">PMC7539940</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwan N.A. Lessons from long COVID: Working with patients to design better research. Nat. Rev. Immunol. 2022;22:201&#x2013;202. doi: 10.1038/s41577-022-00692-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00692-6</ArticleId><ArticleId IdType="pmc">PMC8853146</ArticleId><ArticleId IdType="pubmed">35169259</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballouz T., Menges D., Anagnostopoulos A., Domenghino A., Aschmann H.E., Frei A., Puhan M.A. Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: Population based, longitudinal cohort study. BMJ. 2023;381:e074425. doi: 10.1136/bmj-2022-074425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-074425</ArticleId><ArticleId IdType="pmc">PMC10230608</ArticleId><ArticleId IdType="pubmed">37257891</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E., Levi R., Sarti R., Pozzi C., Mollura M., Mantovani A., Rescigno M. Association Between BNT162b2 Vaccination and long COVID After Infections Not Requiring Hospitalization in Health Care Workers. JAMA. 2022;328:676&#x2013;678. doi: 10.1001/jama.2022.11691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.11691</ArticleId><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner S., Khan M.A., Putrino D., Woodcock A., Kell D.B., Pretorius E. Long COVID: Pathophysiological factors and abnormalities of coagulation. Trends Endocrinol. Metab. 2023;34:321&#x2013;344. doi: 10.1016/j.tem.2023.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2023.03.002</ArticleId><ArticleId IdType="pmc">PMC10113134</ArticleId><ArticleId IdType="pubmed">37080828</ArticleId></ArticleIdList></Reference><Reference><Citation>Talla A., Vasaikar S.V., Szeto G.L., Lemos M.P., Czartoski J.L., MacMillan H., Torgerson T.R. Persistent serum protein signatures define an inflammatory subcategory of long COVID. Nat. Commun. 2023;14:3417. doi: 10.1038/s41467-023-38682-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-38682-4</ArticleId><ArticleId IdType="pmc">PMC10252177</ArticleId><ArticleId IdType="pubmed">37296110</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2022;22:e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Public Health Surveillance for COVID-19: Interim Guidance. WHO; Geneva, Switzerland: 2022.</Citation></Reference><Reference><Citation>Spinicci M., Graziani L., Tilli M., Nkurunziza J., Vellere I., Borchi B., Bartoloni A. Infection with SARS-CoV-2 Variants Is Associated with Different long COVID Phenotypes. Viruses. 2022;14:2367. doi: 10.3390/v14112367.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14112367</ArticleId><ArticleId IdType="pmc">PMC9698829</ArticleId><ArticleId IdType="pubmed">36366465</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B., Sudry T., Flaks-Manov N., Yehezkelli Y., Kalkstein N., Akiva P., Greenfeld S. Long covid outcomes at one year after mild SARS-CoV-2 infection: Nationwide cohort study. BMJ. 2023;380:e072529. doi: 10.1136/bmj-2022-072529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072529</ArticleId><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Bowe B., Xie Y. long COVID after breakthrough SARS-CoV-2 infection. Nat. Med. 2022;28:1461&#x2013;1467. doi: 10.1038/s41591-022-01840-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte K.I., Catahay J.A., Velasco J.V., Pastrana A., Ver A.T., Pangilinan F.C., Fern&#xe1;ndez-de-Las-Pe&#xf1;as C. Impact of COVID-19 vaccination on the risk of developing long COVIDlong COVID and on existing long COVIDlong COVID symptoms: A systematic review. eClinicalMedicine. 2022;53:101624. doi: 10.1016/j.eclinm.2022.101624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Dom&#xe8;nech-Montoliu S., Pac-Sa M.R., Vidal-Utrillas P., Latorre-Poveda M., Del Rio-Gonz&#xe1;lez A., Ferrando-Rubert S., Arnedo-Pena A. Mass gathering events and COVID-19 transmission in Borriana (Spain): A retrospective cohort study. PLoS ONE. 2021;16:e0256747. doi: 10.1371/journal.pone.0256747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0256747</ArticleId><ArticleId IdType="pmc">PMC8389516</ArticleId><ArticleId IdType="pubmed">34437628</ArticleId></ArticleIdList></Reference><Reference><Citation>Dom&#xe8;nech-Montoliu S., Puig-Barber&#xe0; J., Pac-Sa M.R., Vidal-Utrillas P., Latorre-Poveda M., Del Rio-Gonz&#xe1;lez A., Arnedo-Pena A. Complications Post-COVID-19 and Risk Factors among Patients after Six Months of a SARS-CoV-2 Infection: A Population-Based Prospective Cohort Study. Epidemiologia. 2022;3:49&#x2013;67. doi: 10.3390/epidemiologia3010006.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/epidemiologia3010006</ArticleId><ArticleId IdType="pmc">PMC9620887</ArticleId><ArticleId IdType="pubmed">36417267</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministerio de Sanidad  Alertas y Emergencias Sanitarias Alertas de Salud P&#xfa;blica de Actualidad Eventos de Salud P&#xfa;blica en Seguimiento Enfermedad por SARS-CoV-2 (COVID-19) Vacuna COVID-19 Cuadro de Mando Resumen de datos de Vacunaci&#xf3;n.  [(accessed on 8 August 2023)];2023  Available online:  https://www.sanidad.gob.es/areas/alertasEmergenciasSanitarias/alertasActuales/nCov/pbiVacunacion.htm.</Citation></Reference><Reference><Citation>Dom&#xe8;nech-Montoliu S., Puig-Barber&#xe0; J., Pac-Sa M.R., Vidal-Utrillas P., Latorre-Poveda M., Rio-Gonz&#xe1;lez A.D., Arnedo-Pena A. ABO Blood Groups and the Incidence of Complications in COVID-19 Patients: A Population-Based Prospective Cohort Study. Int. J. Environ. Res. Public Health. 2021;18:10039. doi: 10.3390/ijerph181910039.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph181910039</ArticleId><ArticleId IdType="pmc">PMC8507737</ArticleId><ArticleId IdType="pubmed">34639344</ArticleId></ArticleIdList></Reference><Reference><Citation>Dom&#xe8;nech-Montoliu S., Puig-Barber&#xe0; J., Pac-Sa M.R., Vidal-Utrillas P., Latorre-Poveda M., Del Rio-Gonz&#xe1;lez A., Arnedo-Pena A. Persistence of Anti-SARS-CoV-2 Antibodies Six Months after Infection in an Outbreak with Five Hundred COVID-19 Cases in Borriana (Spain): A Prospective Cohort Study. COVID. 2021;1:71&#x2013;82. doi: 10.3390/covid1010006.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/covid1010006</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann W., Latza U., Baumeister S.E., Br&#xfc;nger M., Buttmann-Schweiger N., Hardt J., van den Berg N. Guidelines and recommendations for ensuring Good Epidemiological Practice (GEP): A guideline developed by the German Society for Epidemiology. Eur. J. Epidemiol. 2019;34:301&#x2013;317. doi: 10.1007/s10654-019-00500-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-019-00500-x</ArticleId><ArticleId IdType="pmc">PMC6447506</ArticleId><ArticleId IdType="pubmed">30830562</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Elm E., Altman D.G., Egger M., Pocock S.J., G&#xf8;tzsche P.C., Vandenbroucke J.P. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. PLoS Med. 2007;4:e296. doi: 10.1371/journal.pmed.0040296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0040296</ArticleId><ArticleId IdType="pmc">PMC2020495</ArticleId><ArticleId IdType="pubmed">17941714</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Campayo J., Zamorano E., Ruiz M.A., Pardo A., P&#xe9;rez-P&#xe1;ramo M., L&#xf3;pez-G&#xf3;mez V., Rejas J. Cultural adaptation into Spanish of the generalized anxiety disorder-7 (GAD-7) scale as a screening tool. Health Qual. Life Outcomes. 2010;8:8. doi: 10.1186/1477-7525-8-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-8-8</ArticleId><ArticleId IdType="pmc">PMC2831043</ArticleId><ArticleId IdType="pubmed">20089179</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;we B., Decker O., M&#xfc;ller S., Br&#xe4;hler E., Schellberg D., Herzog W., Herzberg P.Y. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med. Care. 2008;46:266&#x2013;274. doi: 10.1097/MLR.0b013e318160d093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e318160d093</ArticleId><ArticleId IdType="pubmed">18388841</ArticleId></ArticleIdList></Reference><Reference><Citation>Diez-Quevedo C., Rangil T., Sanchez-Planell L., Kroenke K., Spitzer R.L. Validation and utility of the patient health questionnaire in diagnosing mental disorders in 1003 general hospital Spanish inpatients. Psychosom. Med. 2001;63:679&#x2013;686. doi: 10.1097/00006842-200107000-00021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006842-200107000-00021</ArticleId><ArticleId IdType="pubmed">11485122</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F.Y., Chung H., Kroenke K., Delucchi K.L., Spitzer R.L. Using the Patient Health Questionnaire-9 to measure depression among racially and ethnically diverse primary care patients. J. Gen. Intern. Med. 2006;21:547&#x2013;552. doi: 10.1111/j.1525-1497.2006.00409.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1497.2006.00409.x</ArticleId><ArticleId IdType="pmc">PMC1924626</ArticleId><ArticleId IdType="pubmed">16808734</ArticleId></ArticleIdList></Reference><Reference><Citation>Dom&#xe8;nech-Montoliu S., Puig-Barber&#xe0; J., Guerra-Murcia O., Pac-Sa M.R., Orrico-Sanch&#xe9;z A., G&#xf3;mez-Lanas L., Arnedo-Pena A. ABO Blood Groups and Incidence of COVID-19 in the Mass Gathering Events in Borriana (Spain), March 2020: A Retrospective Cohort Study. Epidemiologia. 2023;4:63&#x2013;73. doi: 10.3390/epidemiologia4010007.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/epidemiologia4010007</ArticleId><ArticleId IdType="pmc">PMC9944070</ArticleId><ArticleId IdType="pubmed">36810454</ArticleId></ArticleIdList></Reference><Reference><Citation>National S-C-SAEG Performance characteristics of five immunoassays for SARS-CoV-2: A head-to-head benchmark comparison. Lancet Infect. Dis. 2020;20:1390&#x2013;1400. doi: 10.1016/S1473-3099(20)30634-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30634-4</ArticleId><ArticleId IdType="pmc">PMC7511171</ArticleId><ArticleId IdType="pubmed">32979318</ArticleId></ArticleIdList></Reference><Reference><Citation>Tormo N., Gim&#xe9;nez E., Mart&#xed;nez-Navarro M., Albert E., Navalpotro D., Torres I., Navarro D. Performance comparison of a flow cytometry immunoassay for intracellular cytokine staining and the QuantiFERON(R) SARS-CoV-2 test for detection and quantification of SARS-CoV-2-Spike-reactive-IFN-gamma-producing T cells after COVID-19 vaccination. Eur. J. Clin. Microbiol. Infect. Dis. 2022;41:657&#x2013;662. doi: 10.1007/s10096-022-04422-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-022-04422-7</ArticleId><ArticleId IdType="pmc">PMC8853233</ArticleId><ArticleId IdType="pubmed">35165804</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert E., Burgos J.S., Peir&#xf3; S., Salas D., Vanaclocha H., Gim&#xe9;nez E., Navarro D. Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty(R) COVID-19 vaccine in nursing home residents. Clin. Microbiol. Infect. 2022;28:279&#x2013;284. doi: 10.1016/j.cmi.2021.09.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.09.031</ArticleId><ArticleId IdType="pmc">PMC8490129</ArticleId><ArticleId IdType="pubmed">34619398</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres I., Albert E., Gim&#xe9;nez E., Alcaraz M.J., Botija P., Amat P., Navarro D. B- and T-cell immune responses elicited by the Comirnaty(R) COVID-19 vaccine in nursing-home residents. Clin. Microbiol. Infect. 2021;27:1672&#x2013;1677. doi: 10.1016/j.cmi.2021.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.06.013</ArticleId><ArticleId IdType="pmc">PMC8223011</ArticleId><ArticleId IdType="pubmed">34174397</ArticleId></ArticleIdList></Reference><Reference><Citation>Centro de Coordinaci&#xf3;n de Alertas y Emergencias Sanitarias . Evaluaciones R&#xe1;pidas de Riesgo de las Variantes de SARS-CoV-2 en Espa&#xf1;a. Ministerio de Sanidad; Madrid, Spain: 2023.</Citation></Reference><Reference><Citation>Hodcroft E., CoVariants  Overview of Variants in Countries. Covariants.org.  [(accessed on 17 July 2023)].  Available online:  https://covariants.org/per-country?country=Spain.</Citation></Reference><Reference><Citation>Normand S.L.T., Landrum M.B., Guadagnoli E., Ayanian J.Z., Ryan T.J., Cleary P.D., McNeil B.J. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: A matched analysis using propensity scores. J. Clin. Epidemiol. 2001;54:387&#x2013;398. doi: 10.1016/S0895-4356(00)00321-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0895-4356(00)00321-8</ArticleId><ArticleId IdType="pubmed">11297888</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin P.C. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivar. Behav. Res. 2011;46:399&#x2013;424. doi: 10.1080/00273171.2011.568786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00273171.2011.568786</ArticleId><ArticleId IdType="pmc">PMC3144483</ArticleId><ArticleId IdType="pubmed">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Robins J.M., Hern&#xe1;n M.A., Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550&#x2013;560. doi: 10.1097/00001648-200009000-00011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001648-200009000-00011</ArticleId><ArticleId IdType="pubmed">10955408</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips P.C.B., Park J.Y. On the Formulation of Wald Tests of Nonlinear Restrictions. Econometrica. 1988;56:1065&#x2013;1083. doi: 10.2307/1911359.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/1911359</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V., Elghazaly H., Chattopadhyay R., Debski M., Naing T.K.P., Garg P., Vassiliou V.S. Risk Factors Associated With Post-COVID-19 Condition: A Systematic Review and Meta-analysis. JAMA Intern. Med. 2023;183:566&#x2013;580. doi: 10.1001/jamainternmed.2023.0750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0750</ArticleId><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis R.H., Santillana M., Ognyanova K., Safarpour A., Trujillo K.L., Simonson M.D., Lazer D. Prevalence and Correlates of long COVID Symptoms Among US Adults. JAMA Netw. Open. 2022;5:e2238804. doi: 10.1001/jamanetworkopen.2022.38804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.38804</ArticleId><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S.C., Arthur C.M., Jan H.M., Garcia-Beltran W.F., Patel K.R., Rathgeber M.F., Stowell S.R. Blood group A enhances SARS-CoV-2 infection. Blood. 2023;142:742&#x2013;747. doi: 10.1182/blood.2022018903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022018903</ArticleId><ArticleId IdType="pmc">PMC10294591</ArticleId><ArticleId IdType="pubmed">37367252</ArticleId></ArticleIdList></Reference><Reference><Citation>Santopaolo M., Gregorova M., Hamilton F., Arnold D., Long A., Lacey A., Rivino L. Prolonged T-cell activation and long COVID symptoms independently associate with severe COVID-19 at 3 months. eLife. 2023;12:e85009. doi: 10.7554/eLife.85009.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.85009</ArticleId><ArticleId IdType="pmc">PMC10319436</ArticleId><ArticleId IdType="pubmed">37310006</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann D.M., Whettlock E.M., Liu S., Arachchillage D.J., Boyton R.J. The immunology of long COVID. Nat. Rev. Immunol. 2023 doi: 10.1038/s41577-023-00904-7. ahead-of-print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-023-00904-7</ArticleId><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Moga E., Lynton-Pons E., Domingo P. The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. Front. Immunol. 2022;13:904686. doi: 10.3389/fimmu.2022.904686.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.904686</ArticleId><ArticleId IdType="pmc">PMC9271749</ArticleId><ArticleId IdType="pubmed">35833134</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M., Vetter P., Chappuis F., Kaiser L., Guessous I., CoviCare Study Team Prevalence of Post-Coronavirus Disease Condition 12 Weeks After Omicron Infection Compared With Negative Controls and Association With Vaccination Status. Clin. Infect. Dis. 2023;76:1567&#x2013;1575. doi: 10.1093/cid/ciac947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac947</ArticleId><ArticleId IdType="pubmed">36519381</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe A., Iwagami M., Yasuhara J., Takagi H., Kuno T. Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis. Vaccine. 2023;41:1783&#x2013;1790. doi: 10.1016/j.vaccine.2023.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.02.008</ArticleId><ArticleId IdType="pmc">PMC9905096</ArticleId><ArticleId IdType="pubmed">36774332</ArticleId></ArticleIdList></Reference><Reference><Citation>Byambasuren O., Stehlik P., Clark J., Alcorn K., Glasziou P. Effect of COVID-19 vaccination on long covid: Systematic review. BMJ Med. 2023;2:e000385. doi: 10.1136/bmjmed-2022-000385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2022-000385</ArticleId><ArticleId IdType="pmc">PMC9978692</ArticleId><ArticleId IdType="pubmed">36936268</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Dercon Q., Harrison P.J. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. Brain Behav. Immun. 2022;103:154&#x2013;162. doi: 10.1016/j.bbi.2022.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2022.04.013</ArticleId><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahlert C.R., Strahm C., G&#xfc;sewell S., Cusini A., Brucher A., Goppel S., Kohler P. Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study. Clin. Infect. Dis. 2023;77:194&#x2013;202. doi: 10.1093/cid/ciad143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad143</ArticleId><ArticleId IdType="pmc">PMC10371307</ArticleId><ArticleId IdType="pubmed">36905145</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynberg E., Han A.X., Boyd A., van Willigen H.D., Verveen A., Lebbink R., RECoVERED Study Group The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study. Vaccine. 2022;40:4424&#x2013;4431. doi: 10.1016/j.vaccine.2022.05.090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.05.090</ArticleId><ArticleId IdType="pmc">PMC9170535</ArticleId><ArticleId IdType="pubmed">35725782</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney L.L., Routen A., Gillies C., Ekezie W., Welford A., Zhang A., Karamchandani U., Simms-Williams N., Cassambai S., Ardavani A., et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine. 2023;55:101762. doi: 10.1016/j.eclinm.2022.101762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard S.A., Pollett S.D., Fries A.C., Berjohn C.M., Maves R.C., Lalani T., Lago K. Persistent COVID-19 Symptoms at 6 Months After Onset and the Role of Vaccination Before or After SARS-CoV-2 Infection. JAMA Netw. Open. 2023;6:e2251360. doi: 10.1001/jamanetworkopen.2022.51360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.51360</ArticleId><ArticleId IdType="pmc">PMC9857077</ArticleId><ArticleId IdType="pubmed">36652247</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>